Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Medifast (MED) Equity Average (2016 - 2025)

Historic Equity Average for Medifast (MED) over the last 15 years, with Q4 2025 value amounting to $206.8 million.

  • Medifast's Equity Average fell 91.63% to $206.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $206.8 million, marking a year-over-year decrease of 91.63%. This contributed to the annual value of $204.5 million for FY2025, which is 62.22% down from last year.
  • Medifast's Equity Average amounted to $206.8 million in Q4 2025, which was down 91.63% from $215.4 million recorded in Q3 2025.
  • Over the past 5 years, Medifast's Equity Average peaked at $215.4 million during Q3 2025, and registered a low of $140.0 million during Q3 2022.
  • Moreover, its 5-year median value for Equity Average was $198.3 million (2021), whereas its average is $191.2 million.
  • As far as peak fluctuations go, Medifast's Equity Average soared by 6246.35% in 2021, and later tumbled by 2837.61% in 2022.
  • Medifast's Equity Average (Quarter) stood at $199.4 million in 2021, then fell by 23.36% to $152.8 million in 2022, then increased by 29.11% to $197.3 million in 2023, then grew by 5.81% to $208.7 million in 2024, then decreased by 0.92% to $206.8 million in 2025.
  • Its last three reported values are $206.8 million in Q4 2025, $215.4 million for Q3 2025, and $213.5 million during Q2 2025.